- Home
- RMCF vs BLRX Comparison
RMCF vs BLRX Comparison
Compare RMCF & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- BLRX
- Stock Information
- Founded
- RMCF 1981
- BLRX 2003
- Country
- RMCF United States
- BLRX Israel
- Employees
- RMCF N/A
- BLRX N/A
- Industry
- RMCF Specialty Foods
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- BLRX Health Care
- Exchange
- RMCF Nasdaq
- BLRX Nasdaq
- Market Cap
- RMCF 13.3M
- BLRX 12.2M
- IPO Year
- RMCF N/A
- BLRX 2011
- Fundamental
- Price
- RMCF $1.20
- BLRX $2.94
- Analyst Decision
- RMCF
- BLRX Buy
- Analyst Count
- RMCF 0
- BLRX 2
- Target Price
- RMCF N/A
- BLRX $26.00
- AVG Volume (30 Days)
- RMCF 43.2K
- BLRX 26.4K
- Earning Date
- RMCF 01-14-2025
- BLRX 05-27-2025
- Dividend Yield
- RMCF N/A
- BLRX N/A
- EPS Growth
- RMCF N/A
- BLRX N/A
- EPS
- RMCF N/A
- BLRX N/A
- Revenue
- RMCF $27,939,687.00
- BLRX $28,940,000.00
- Revenue This Year
- RMCF N/A
- BLRX N/A
- Revenue Next Year
- RMCF N/A
- BLRX N/A
- P/E Ratio
- RMCF N/A
- BLRX N/A
- Revenue Growth
- RMCF N/A
- BLRX 502.92
- 52 Week Low
- RMCF $1.20
- BLRX $2.85
- 52 Week High
- RMCF $3.92
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- RMCF 31.59
- BLRX 38.75
- Support Level
- RMCF $1.20
- BLRX $3.01
- Resistance Level
- RMCF $1.44
- BLRX $3.61
- Average True Range (ATR)
- RMCF 0.09
- BLRX 0.21
- MACD
- RMCF 0.01
- BLRX 0.02
- Stochastic Oscillator
- RMCF 6.45
- BLRX 17.11
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.